跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Philippines FDA
/
Imbruvica
Approved
STANDARD
Imbruvica
Cilag AG
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
a0712f0bdbaa2d64
Company
Cilag AG
Type
Standard
Approval Details
Approval Id
a0712f0bdbaa2d64
Drug Approval Philippines Name
Imbruvica
Product Name
Imbruvica
Registration Number
DR-XY48675
Brand Name
Imbruvica
Generic Name
Ibrutinib
Dosage Form
Film-Coated Tablet
Dosage Strength
140 mg
Manufacturer
Cilag AG
Importer
Johnson & Johnson (Philippines), Inc.
Company Detail Path
/organization/cilag-ag
Issuance Date
28 September 2023
Expiry Date
30 March 2028
Pharmacologic Category
Antineoplastic Agent (Protein Kinase Inhibitor)
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
a0712f0bdbaa2d64
Type
Standard
Back to Philippines FDA Approvals
Imbruvica - Philippines FDA Drug Approval Details